Microbiota transplant therapy and autism: lessons for the clinic

Expert Rev Gastroenterol Hepatol. 2019 Nov;13(11):1033-1037. doi: 10.1080/17474124.2019.1687293. Epub 2019 Nov 7.


Introduction: The purpose of this review is to discuss Microbiota Transplant Therapy (MTT), a type of intensive intestinal microbiota transplantation (IMT), for people with autism spectrum disorders (ASD) and chronic gastrointestinal disorders (constipation and/or diarrhea).Areas covered: This paper briefly reviews IMT, gastrointestinal symptoms and gastrointestinal bacteria in children with ASD, and results and lessons learned from intensive MTT for autism.Expert opinion: An open-label study and a two-year follow-up suggest that MTT is relatively safe and effective in significantly reducing gastrointestinal disorders and autism symptoms, changing the gut microbiome structure, and increasing gut microbial diversity. Further research with larger, randomized, double-blind, placebo-controlled studies is warranted.

Keywords: Autism; constipation; diarrhea; fecal microbiota transplant; gastrointestinal symptoms; intestinal microbiota transplant; microbiota transplant therapy; vancomycin.

Publication types

  • Review

MeSH terms

  • Autism Spectrum Disorder / diagnosis
  • Autism Spectrum Disorder / microbiology
  • Autism Spectrum Disorder / psychology
  • Autism Spectrum Disorder / therapy*
  • Chronic Disease
  • Constipation / diagnosis
  • Constipation / microbiology
  • Constipation / therapy*
  • Diarrhea / diagnosis
  • Diarrhea / microbiology
  • Diarrhea / therapy*
  • Dysbiosis
  • Fecal Microbiota Transplantation* / adverse effects
  • Gastrointestinal Microbiome*
  • Humans
  • Treatment Outcome